Drugs Made In America Acquisition Corp. — Form 8-K

On July 14, 2026, Drugs Made In America Acquisition Corp. (DMAA, $234.6M public market value) executed Omnibus Amendment No. 3 to its April 29, 2026 merger agreement with Power Analytics Global Corp. (PAGC). The amendment restructures capitalization (13,559,770 public shares remain after 9.4M share redemptions totaling $99.3M), mandates sponsor forfeiture of ≥50% of founder shares, addresses rights conversions, raises financing capacity to $150M PIPE plus $1.5M working capital loans, sets $15M–$30M minimum cash at close, and pre-approves a contingent Amendment No. 4 for a three-party combination with an unnamed 'Additional Target' at a combined $3B equity value (allocation between PAGC and Additional Target unfixed), conditioned on LOI execution by September 30, 2026. The deal involves BV Advisory Partners, LLC, holding convertible notes and sponsor-level economics (≥40%), creating an affiliate transaction requiring fairness opinion and independent director approval.